Jeffrey N Myers Selected Research

AEE 788 (AEE788)

11/2006	Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
6/2006	Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
6/2005	Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
4/2005	Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
3/2005	AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
11/2004	Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey N Myers Research Topics

Disease

151	Neoplasms (Cancer) 02/2024 - 08/2002
101	Squamous Cell Carcinoma of Head and Neck 10/2023 - 12/2002
34	Neoplasm Metastasis (Metastasis) 01/2024 - 12/2002
29	Head and Neck Neoplasms (Head and Neck Cancer) 10/2023 - 08/2002
23	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2023 - 08/2002
19	Mouth Neoplasms (Oral Cancer) 01/2022 - 08/2002
13	Anaplastic Thyroid Carcinoma 01/2019 - 12/2004
12	Melanoma (Melanoma, Malignant) 01/2023 - 03/2002
11	Carcinogenesis 11/2021 - 12/2006
11	Carcinoma (Carcinomatosis) 01/2021 - 03/2004
6	Lymphatic Metastasis 03/2013 - 04/2003
4	Oropharyngeal Neoplasms 02/2024 - 11/2015
4	Mucositis 02/2024 - 11/2012
4	Adenoid Cystic Carcinoma (Cylindroma) 08/2019 - 01/2004
4	Hypoxia (Hypoxemia) 12/2015 - 09/2005
4	Thyroid Neoplasms (Thyroid Cancer) 04/2009 - 12/2004
3	Bites and Stings (Sting) 01/2024 - 01/2021
3	Inflammation (Inflammations) 01/2024 - 09/2004
3	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2017 - 10/2009
2	Dysgeusia (Parageusia) 02/2024 - 12/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 09/2005
2	Sinonasal undifferentiated carcinoma 10/2019 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 04/2018 - 03/2017
2	Extranodal Extension 01/2017 - 04/2003

Drug/Important Bio-Agent (IBA)

26	Proteins (Proteins, Gene)FDA Link 01/2024 - 11/2004
25	Biomarkers (Surrogate Marker)IBA 10/2020 - 02/2005
24	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2006
21	ErbB Receptors (EGF Receptor)IBA 01/2020 - 08/2002
13	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2006
13	Paclitaxel (Taxol)FDA LinkGeneric 03/2012 - 08/2003
11	Phosphotransferases (Kinase)IBA 01/2021 - 03/2005
10	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 06/2007
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 11/2004
8	Epidermal Growth Factor (EGF)IBA 05/2014 - 08/2002
8	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 04/2011 - 04/2005
7	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2009 - 03/2005
6	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2017
6	Docetaxel (Taxotere)FDA Link 11/2022 - 02/2013
6	Tyrosine Kinase InhibitorsIBA 11/2014 - 12/2005
6	AEE 788 (AEE788)IBA 11/2006 - 11/2004
5	Messenger RNA (mRNA)IBA 01/2023 - 10/2014
5	Monoclonal AntibodiesIBA 01/2021 - 10/2008
5	Protons (Proton)IBA 01/2021 - 01/2017
5	LigandsIBA 12/2017 - 08/2006
5	vandetanib (ZD6474)IBA 03/2016 - 08/2008
4	InterferonsIBA 01/2024 - 01/2021
4	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2017
4	adavosertibIBA 01/2021 - 02/2015
4	MicroRNAs (MicroRNA)IBA 12/2020 - 11/2011
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2020 - 02/2005
4	Metformin (Glucophage)FDA LinkGeneric 01/2016 - 01/2012
4	Fluorouracil (Carac)FDA LinkGeneric 07/2015 - 11/2012
4	Mitogen-Activated Protein KinasesIBA 06/2010 - 06/2005
4	Irinotecan (Camptosar)FDA LinkGeneric 08/2006 - 12/2005
3	PlatinumIBA 10/2023 - 04/2015
3	Interleukin-6 (Interleukin 6)IBA 07/2023 - 09/2006
3	Adrenergic Agents (Adrenergic Drugs)IBA 01/2023 - 01/2020
3	Small Interfering RNA (siRNA)IBA 01/2023 - 01/2016
3	CytokinesIBA 01/2023 - 06/2010
3	CarcinogensIBA 03/2021 - 01/2010
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 06/2010
3	Gefitinib (Iressa)FDA Link 01/2019 - 12/2004
3	EnzymesIBA 01/2016 - 02/2012
3	Bevacizumab (Avastin)FDA Link 12/2013 - 04/2007
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2011 - 11/2004
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 06/2010 - 04/2006
3	CurcuminIBA 03/2010 - 09/2004
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2005 - 11/2004
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2024 - 01/2021
2	Programmed Cell Death 1 ReceptorIBA 01/2023 - 01/2022
2	Glutamine (L-Glutamine)FDA Link 01/2023 - 07/2011
2	Keratins (Keratin)IBA 01/2023 - 02/2005
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2022 - 11/2014
2	mu Opioid Receptors (mu Opioid Receptor)IBA 11/2021 - 08/2021
2	niraparibIBA 01/2021 - 01/2020
2	Nerve Growth Factor (NGF)IBA 01/2021 - 12/2020
2	Death Domain ReceptorsIBA 01/2021 - 12/2017
2	Formaldehyde (Formol)FDA Link 10/2019 - 01/2014
2	ParaffinIBA 10/2019 - 01/2014
2	Annexin A5IBA 01/2019 - 09/2004
2	Fluorescein-5-isothiocyanate (FITC)IBA 01/2019 - 11/2011
2	TransferasesIBA 01/2019 - 01/2006
2	Insulin-Like PeptidesIBA 01/2019 - 01/2006
2	AMP-Activated Protein KinasesIBA 01/2018 - 06/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2017 - 04/2007
2	Lactic Acid (Lactate)FDA LinkGeneric 03/2017 - 12/2015

Therapy/Procedure

67	Therapeutics 10/2023 - 01/2002
32	Radiotherapy 04/2024 - 08/2003
17	Drug Therapy (Chemotherapy) 10/2023 - 04/2006
13	Neck Dissection (Radical Neck Dissection) 09/2022 - 12/2002
9	Induction Chemotherapy 04/2022 - 11/2012
6	Chemoradiotherapy 11/2022 - 10/2009
6	Molecular Targeted Therapy 03/2011 - 08/2002
4	Immunotherapy 01/2023 - 01/2017
3	Aftercare (After-Treatment) 02/2024 - 09/2016
3	Neoadjuvant Therapy 07/2023 - 06/2013
3	Adjuvant Radiotherapy 02/2011 - 08/2003
3	Lasers (Laser) 10/2008 - 11/2004
2	Laryngectomy 11/2020 - 01/2006
2	Free Tissue Flaps 06/2018 - 01/2006